Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis of 92.1-parental and 92.1-resistant uveal melanoma cells

ABSTRACT: To study the mechanism of cisplatin resistance in uveal melanoma, we performed RNA-seq of 92.1-parental and 92.1-resistant uveal melanoma cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE271497 | GEO | 2026/01/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

H3K9ac and H3K27ac analysis of 92.1-parental and 92.1-resistant uveal melanoma cells

Project description:To study the mechanism of cisplatin resistance in uveal melanoma, we performed H3K9ac and H3K27ac Cut&Tag in 92.1-parental and 92.1-resistant uveal melanoma cells.

2026-01-01 | GSE271539 | GEO

Transcriptome analysis of 92.1-parental and 92.1-resistant uveal melanoma cells

Project description:Transcriptome analysis of 92.1-parental and 92.1-resistant uveal melanoma cells

| PRJNA1131825 | ENA

H3K9ac and H3K27ac analysis of 92.1-parental and 92.1-resistant uveal melanoma cells

Project description:H3K9ac and H3K27ac analysis of 92.1-parental and 92.1-resistant uveal melanoma cells

| PRJNA1132184 | ENA

RNA-seq analysis in uveal melanoma cells 92.1 and OMM1

Project description:RNA-seq analysis in uveal melanoma cells 92.1 and OMM1

| PRJNA765665 | ENA

RNA-seq analysis of uveal melanoma cells treated with FR900359

Project description:FR900359 is an allosteric inhibitor of Gq. 92.1 uveal melanoma cells, which are driven by constitutively active Gq, were treated with 100 nM FR900359 or vehicle for 1 day and 3days. RNA-seq was performed.

2018-10-01 | GSE103761 | GEO

RNA-seq analysis in uveal melanoma cells 92.1 and OMM1

Project description:The goals of this study are to compare gene expression profiles between uveal melanoma cells treated with either a scrambled antisense oligonucleotide (NTC) or a SAMMSON inhibiting ASO wether or not in combination with mTOR inhibitor GDC-0349. GDC-0349 synergizes with SAMMSON ASO to further reduce cell viability. Based on the RNA seq data, we observed only a limited number of DEGs in the GDC-0349 treated cells, while the number of DEGs in the combination significantly increased compared to SAMMSON ASO alone with many overlapping genes showing a more pronounced log2foldchange.

2022-09-24 | GSE184685 | GEO

Karyotyping using SNP array of primary uveal melanoma cells, normal uveal melanocytes, neural crest stem cells, embryonic stem cells and uveal melanoma cell lines MUM2B and OCM1A

Project description:Karyotyping by SNP array of primary uveal melanoma samples, uveal melanoma cell lines and normal controls The Human660WQuad v1.0 DNA Analysis Bead Chip and kit were used for high resolution molecular karyotyping of DNA isolated from snap-frozen primary uveal melanoma tissue isolated from enucleated eyes.

2013-02-14 | E-GEOD-44297 | biostudies-arrayexpress

Selamectin increases cisplatin sensitivity by inhibiting cisplatin-resistant genes expression and autophagy in uveal melanoma

Project description:Cisplatin resistance is the main reason for uveal melanoma (UM) treatment failure. Thus, developing strategy that increasing cisplatin sensitivity is needed. In this study, we performed drug repositioning analysis with the Connectivity Map database using a panel of previously identified cisplatin sensitivity–associated genes and cisplatin resistance–associated genes as the signature and obtained the antiparasitic drug selamectin. We demonstrated that the selamectin and cisplatin combination showed a synergistic effect on inhibiting UM cell growth. Experiments in tumor-bearing nude mice further showed that selamectin and cisplatin have synergistic effects in reducing tumor growth. Previous studies have linked increased autophagy with tumor resistance to chemotherapy. We found that selamectin inhibited the expression of the autophagy-related gene ATG9B, thus reducing autophagy. The cisplatin resistance–associated genes PDGFRB, DUSP1, MAST1 and IL11 were significantly downregulated in UM cells treated with selamectin. In summary, our study shows that selamectin enhanced the sensitivity of UM to cisplatin, through the mechanism of inhibiting cisplatin resistance–associated gene expression and autophagy. These findings may provide a new strategy for the treatment of UM.

2025-01-01 | GSE228250 | GEO

Epigenome analysis of primary uveal melanoma cells, normal uveal melanocytes, neural crest stem cells, embryonic stem cells and uveal melanoma cell lines

Project description:Genome wide DNA methylation profiling of primary uveal melanoma cells, normal uveal melanocytes, neural crest stem cells, embryonic stem cells and uveal melanoma cell lines. The Illumina Infinium 27k Human DNA methylation Beadchip Rev B was used to obtain DNA methylation profiles across approximately 27,000 CpGs in the samples. Samples included 58 primary UM, 3 NUM and NCSC controls and 2 cell lines. Bisulphite converted DNA from the 63 samples were hybridised to the Illumina Infinium 27k Human Methylation Beadchip Rev B

2013-02-14 | E-GEOD-44296 | biostudies-arrayexpress

Expression data from Uveal Melanoma

Project description:Despite advances in surgery and radiotherapy of uveal melanoma (UM), many patients develop distant metastases that poorly respond to therapy. Improved therapies for the metastatic disease are therefore urgently needed. Expression of the epidermal growth factor receptor (EGFR), a target of kinase inhibitors and humanized antibodies in use for several cancers, had been reported. 48 human UMs were analyzed by expression profiling. Evidence for signaling in tumors was obtained through the application of a UM-specific EGF signature. The EGFR specific kinase inhibitor, Gefitinib, and the humanized monoclonal antibody, Cetuximab, were tested for their effect on EGFR signaling. Natural killer cell mediated antibody-dependent cellular cytotoxicity (ADCC) and TNF-alpha release was analyzed for Cetuximab. EGFR appears suited as a novel molecular drug target for therapy of uveal melanoma. Gene expression profiles of 19 unique samples from uveal melanoma patients were measured.

2013-11-18 | E-GEOD-51880 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data